61 related articles for article (PubMed ID: 33421923)
1. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
Lobefaro R; Viscardi G; Di Liello R; Massa G; Iacovino ML; Sparano F; Della Corte CM; Ferrara R; Signorelli D; Proto C; Prelaj A; Galli G; De Toma A; Brambilla M; Ganzinelli M; Trevisan B; Ciardiello F; De Braud F; Morgillo F; Garassino MC; Lo Russo G
Lung Cancer; 2021 Feb; 152():165-173. PubMed ID: 33421923
[TBL] [Abstract][Full Text] [Related]
2. [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease].
Bi ZK; Xu Y; Guo L; Zhang WJ; You YT; Li JW; Zhao CL; Shan YF; Xia TT; Li YF; Xu Z; Fan Y; Bai L
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1601-1609. PubMed ID: 38742347
[No Abstract] [Full Text] [Related]
3. Diagnosis, testing, treatment, and outcomes among patients with advanced non-small cell lung cancer in the United States.
Yang M; MacEwan JP; Boppudi SS; McClain MR; O'Hara RM; Paik PK
Cancer Med; 2023 Dec; 12(24):21605-21614. PubMed ID: 38062905
[TBL] [Abstract][Full Text] [Related]
4. Combination of immunotherapy, radiotherapy and denosumab as the best approach even for NSCLC poor prognosis patients: a case report with strong response, prolonged survival and a review of literature.
De Felice M; Turitto G; Borrelli C; Menditto C; Cangiano R
Curr Probl Cancer; 2023 Dec; 47(6):100947. PubMed ID: 36681616
[TBL] [Abstract][Full Text] [Related]
5. Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients.
Heo JY; Yoo SH; Suh KJ; Kim SH; Kim YJ; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
Sci Rep; 2021 Jan; 11(1):2514. PubMed ID: 33510255
[TBL] [Abstract][Full Text] [Related]
6. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Malapelle U; Passiglia F; Cremolini C; Reale ML; Pepe F; Pisapia P; Avallone A; Cortinovis D; De Stefano A; Fassan M; Fontanini G; Galetta D; Lauricella C; Listì A; Loupakis F; Pagni F; Pietrantonio F; Pilotto S; Righi L; Bianchi AS; Parra HS; Tiseo M; Verzè M; Troncone G; Novello S
Eur J Cancer; 2021 Mar; 146():74-83. PubMed ID: 33588147
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.
Ciardiello D; Blauensteiner B; Matrone N; Belli V; Mohr T; Vitiello PP; Martini G; Poliero L; Cardone C; Napolitano S; De Falco V; Giunta EF; Ciaramella V; Corte CD; Barra G; Selvaggi F; Franco R; Marino FZ; Cuomo A; Morgillo F; Troiani T; Sibilia M; Ciardiello F; Martinelli E
Med Oncol; 2021 Feb; 38(3):24. PubMed ID: 33570712
[TBL] [Abstract][Full Text] [Related]
8. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Pensieri MV; Russano M; Cantini L; Nigro O; Leonetti A; Bordi P; Minuti G; Landi L; De Toma A; Donisi C; Ricciardi S; Migliorino MR; Napoli VM; Leone G; Metro G; Banna GL; Friedlaender A; Addeo A; Ficorella C; Porzio G
Thorac Cancer; 2021 Mar; 12(6):880-889. PubMed ID: 33527756
[TBL] [Abstract][Full Text] [Related]
9. Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors.
Beninato T; Fucà G; Di Guardo L; Vetrano I; Valeri B; Nesa F; Del Vecchio M; Cimminiello C
Melanoma Res; 2021 Apr; 31(2):178-180. PubMed ID: 33492050
[TBL] [Abstract][Full Text] [Related]
10. Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.
Hashemi S; Fransen MF; Niemeijer A; Ben Taleb N; Houda I; Veltman J; Becker-Commissaris A; Daniels H; Crombag L; Radonic T; Jongeneel G; Tarasevych S; Looysen E; van Laren M; Tiemessen M; van Diepen V; Maassen-van den Brink K; Thunnissen E; Bahce I
Lung Cancer; 2021 Mar; 153():81-89. PubMed ID: 33465698
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
[TBL] [Abstract][Full Text] [Related]
12. Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data.
Jemielita T; Li XN; Piperdi B; Zhou W; Burke T; Chen C
JCO Clin Cancer Inform; 2021 Jan; 5():56-65. PubMed ID: 33439727
[TBL] [Abstract][Full Text] [Related]
13. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
14. Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.
Hurkmans DP; Verdegaal EME; Hogan SA; de Wijn R; Hovestad L; van den Heuvel DMA; Ruijtenbeek R; Welters MJP; van Brakel M; Basak EA; Pinedo HM; Lamers CHJ; van de Werken HJG; Groten JP; Debets R; Levesque MP; Dummer R; Kapiteijn E; Mathijssen RHJ; Aerts JGJV; van der Burg SH
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33427690
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
16. Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
Attili I; Tarantino P; Passaro A; Stati V; Curigliano G; de Marinis F
Lung Cancer; 2021 Apr; 154():151-160. PubMed ID: 33684660
[TBL] [Abstract][Full Text] [Related]
17. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
Chan SWS; Smith E; Aggarwal R; Balaratnam K; Chen R; Hueniken K; Fazelzad R; Weiss J; Jiang S; Shepherd FA; Bradbury PA; Sacher AG; Leighl NB; Xu W; Brown MC; Eng L; Liu G
Clin Lung Cancer; 2021 Sep; 22(5):390-407. PubMed ID: 33582072
[TBL] [Abstract][Full Text] [Related]
18. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Li N; Zheng X; Gan J; Zhuo T; Li X; Yang C; Wu Y; Qin S
Chin Med J (Engl); 2023 Nov; 136(21):2562-2572. PubMed ID: 37925595
[TBL] [Abstract][Full Text] [Related]
19. Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer.
Cheng M; Yang F; Yang Y; Gao X; Yu Y; Wang N; Luo X; Zhang S; Jiang S; Dong M
Cancer Chemother Pharmacol; 2024 Jan; 93(1):31-39. PubMed ID: 37740797
[TBL] [Abstract][Full Text] [Related]
20. The expression panel of CXCL9, GBP5, and IFNG is a potential pan-cancer biomarker to predict immunotherapy response.
Wang J; Zhou Y; Yang Y; Wu Z
Am J Transl Res; 2023; 15(6):3960-3975. PubMed ID: 37434847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
